The Rigor of Evidence: Why Cancer Research Demands More Than Anecdotal Signals
A critical review by Alfonso Dueñas Gonzalez, Medical Oncologist and Senior Researcher at the National Cancer Institute of Mexico, is sparking debate within the oncology community. His analysis, shared on X, dissects a preprint study claiming positive outcomes with a compounded protocol of ivermectin and mebendazole. Dr. Dueñas Gonzalez’s core argument: promising anecdotal signals aren’t enough. Rigorous, well-controlled clinical trials are essential before any treatment can be considered viable.
The Problem with “Lost” Patients and Selection Bias
One of the most significant concerns raised by Dr. Dueñas Gonzalez is the high attrition rate in the preprint study. Of 197 patients enrolled, only 122 (61.9%) completed the 6-month follow-up. This loss of 75 patients (38.1%) introduces a substantial bias. In oncology, dropouts frequently correlate with disease progression or death. Focusing solely on the patients who remained and reported positive results creates a skewed perception of success, rendering the reported 84.4% success rate statistically unreliable.
Dosing Dilemmas: Are We Using Enough – Or Too Little?
The study’s apply of sub-therapeutic doses of both ivermectin (25mg) and mebendazole (250mg) is another key point of contention. Dr. Dueñas Gonzalez points out that existing pharmacokinetic (PK) data suggests the ivermectin dose is significantly lower than what’s been proven safe and potentially necessary for systemic anti-cancer activity. Studies indicate ivermectin is safe up to 2mg/kg (around 140mg for a 70kg adult). Similarly, the mebendazole dose falls far short of the Maximum Tolerated Dose (MTD) used in brain cancer trials – up to 4,800mg/day has been utilized to improve bioavailability.
The Importance of Verified Endpoints in Cancer Trials
Reliable data is the cornerstone of medical advancement. The preprint study relied on voluntary digital surveys to capture primary endpoints like regression and “No Evidence of Disease,” without radiographic evidence (CT/MRI) or medical record verification. This lack of objective confirmation is problematic. A substantial portion of patients receiving the protocol were also undergoing conventional treatments like chemotherapy (27.9%), radiation (21.3%), or surgery (19.7%). Without a control group, it’s impossible to determine whether any observed benefits are attributable to the experimental protocol or standard-of-care treatments.
Ethical Considerations and Potential Conflicts of Interest
Dr. Dueñas Gonzalez also highlights ethical concerns regarding the study’s IRB exemption, arguing that prospective interventional data collection on vulnerable cancer patients requires formal ethical oversight. He further points to a potential conflict of interest, as all authors are affiliated with The Wellness Company, which sells the compounded protocol. This financial connection raises questions about objectivity and necessitates a high degree of skepticism.
Future Trends in Cancer Research: A Focus on Rigor and Precision
This critique underscores a growing trend in cancer research: a demand for increasingly rigorous methodologies and a rejection of premature conclusions based on limited or flawed data. Several key areas are gaining prominence:
- Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling: Predicting how drugs behave in the body and their effects is becoming crucial for optimizing dosing and maximizing efficacy.
- Liquid Biopsies and Circulating Biomarkers: Analyzing circulating tumor DNA (ctDNA) and other biomarkers offers a non-invasive way to monitor treatment response and detect early signs of recurrence. Dr. Dueñas Gonzalez’s work, as highlighted by his Google Scholar profile, focuses on circulating DNA.
- Personalized Medicine and Genomic Profiling: Tailoring treatment to an individual’s genetic makeup is becoming increasingly feasible, allowing for more targeted and effective therapies.
- Data Transparency and Reproducibility: Open access to data and a commitment to reproducible research are essential for building trust and accelerating scientific progress.
Pro Tip:
Always critically evaluate the source of medical information. Look for peer-reviewed studies published in reputable journals and be wary of claims based solely on anecdotal evidence.
FAQ: Understanding Cancer Research and Evidence-Based Medicine
- What is a preprint? A preprint is a complete scientific manuscript posted publicly before peer review. It allows for rapid dissemination of research but hasn’t been vetted by experts.
- Why are clinical trials important? Clinical trials are carefully designed studies that evaluate the safety and efficacy of new treatments.
- What is attrition in a clinical trial? Attrition refers to the loss of participants during a study, which can introduce bias if not properly addressed.
- What does “sub-therapeutic dose” signify? It refers to a dose of a drug that is lower than the amount typically used to achieve a therapeutic effect.
Did you recognize? Alfonso Dueñas Gonzalez has been cited over 12,150 times, demonstrating his significant contribution to the field of oncology.
Want to learn more about the latest advancements in cancer research? Explore more articles on OncoDaily and stay informed.
Worth a look